ForPatients
by Roche

Juvenile Idiopathic Arthritis

A Study of Subcutaneously Administered Tocilizumab in Participants With Systemic Juvenile Idiopathic Arthritis

Trial Status	Trial Runs In	Trial Identifier
Completed	12 Countries	NCT01904292 2012-003490-26 WA28118

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This open-label, multicenter study will evaluate the pharmacokinetics, pharmacodynamics, and safety of subcutaneously administered tocilizumab in participants with Systemic Juvenile Idiopathic Arthritis (sJIA). Participants with body weight less than (<) 30 kilograms (kg) will receive subcutaneous (SC) tocilizumab dose every 2 weeks (Q2W) and participants with body weight greater than or equal to (>=) 30 kg will receive weekly (QW), for 52 weeks. Tocilizumab was administered every 10 days until pre-planned interim analysis was performed and changed to Q2W in participants with body weight <30 kg.

Hoffmann-La Roche	Phase 1
Sponsor	Phase

NCT01904292 2012-003490-26 WA28118
Trial Identifiers

Eligibility Criteria:

Gender	Age	Healthy Volunteers
All	>=1 Year & <= 17 Years	No

© 2022 F. Hoffmann-La Roche Ltd